Yarrow Bioscience files amended 8-K report on merger exchange ratio update

• Yarrow Bioscience filed an amended Form 8-K to update its audited financial statements to reflect the effects of the merger exchange ratio disclosed in Note 1.
• Baker Tilly’s audit opinion remained unqualified, with the report dated March 31, 2026 and a revised date of Aug. 13, 2026 for the exchange-ratio effects.
• The filing also reflects the completed merger on July 27, 2026, when VYNE issued 2,130,731 shares of common stock based on an exchange ratio of 0.7171.
• The transaction was accounted for as a reverse recapitalization, with Yarrow treated as the accounting acquirer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yarrow Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-095925), on August 13, 2026, and is solely responsible for the information contained therein.